Yesterday’s New York Times had an article that described how pharmaceutical companies are dragging their heels on a drug that could save thousands of lives annually. The drug’s problem? It’s cheap.
[I]ts very inexpensiveness has slowed its entry into American emergency rooms, where it might save the lives of bleeding victims of car crashes, shootings and stabbings — up to 4,000 Americans a year, according to a recent study.
Because there is so little profit in it, the companies that make it do not champion it.